ID   CHK2_HUMAN              Reviewed;         543 AA.
AC   O96017; A8K3Y9; B7ZBF3; B7ZBF4; B7ZBF5; Q6QA03; Q6QA04; Q6QA05;
AC   Q6QA06; Q6QA07; Q6QA08; Q6QA10; Q6QA11; Q6QA12; Q6QA13; Q9HCQ8;
AC   Q9UGF0; Q9UGF1;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   02-NOV-2010, entry version 132.
DE   RecName: Full=Serine/threonine-protein kinase Chk2;
DE            EC=2.7.11.1;
DE   AltName: Full=Cds1;
GN   Name=CHEK2; Synonyms=CHK2, RAD53;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF ASP-347.
RX   MEDLINE=99055399; PubMed=9836640; DOI=10.1126/science.282.5395.1893;
RA   Matsuoka S., Huang M., Elledge S.J.;
RT   "Linkage of ATM to cell cycle regulation by the Chk2 protein kinase.";
RL   Science 282:1893-1897(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   MEDLINE=99108191; PubMed=9889122; DOI=10.1016/S0960-9822(99)80041-4;
RA   Blasina A., van de Weyer I., Laus M.C., Luyten W.H.M.L., Parker A.E.,
RA   McGowan C.H.;
RT   "A human homologue of the checkpoint kinase Cds1 directly inhibits
RT   Cdc25 phosphatase.";
RL   Curr. Biol. 9:1-10(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND FUNCTION.
RX   MEDLINE=99199255; PubMed=10097108; DOI=10.1073/pnas.96.7.3745;
RA   Brown A.L., Lee C.-H., Schwarz J.K., Mitiku N., Piwnica-Worms H.,
RA   Chung J.H.;
RT   "A human Cds1-related kinase that functions downstream of ATM protein
RT   in the cellular response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:3745-3750(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3; 4; 5; 6; 7; 8; 9; 10; 11
RP   AND 12), FUNCTION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Mammary gland;
RX   PubMed=15361853; DOI=10.1038/sj.onc.1207928;
RA   Staalesen V., Falck J., Geisler S., Bartkova J., Boerresen-Dale A.-L.,
RA   Lukas J., Lillehaug J.R., Bartek J., Lonning P.E.;
RT   "Alternative splicing and mutation status of CHEK2 in stage III breast
RT   cancer.";
RL   Oncogene 23:8535-8544(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 9).
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Colon carcinoma;
RA   Shao R.-G., Zhang H., Yu Q., Pommier Y.;
RT   "Chk2/HuCds1 cell cycle checkpoint protein kinase from human colon
RT   carcinoma HT29 cells: regulation by autophosphorylation and DNA-
RT   dependent protein kinase and inhibition by cell cycle regulatory
RT   drugs.";
RL   Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 12).
RC   TISSUE=T-cell;
RA   Ogawa A., Okabe-Nakamura A.;
RT   "An alternative spliced Chk2.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-85; THR-157;
RP   MET-436; LYS-446; ILE-447; SER-448; LYS-501 AND VAL-512.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=20057165; PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   ENZYME REGULATION, PHOSPHORYLATION AT THR-68, AND MUTAGENESIS OF
RP   THR-68 AND ASP-368.
RX   PubMed=15342622; DOI=10.1074/jbc.M409961200;
RA   Tosti E., Waldbaum L., Warshaw G., Gross E.A., Ruggieri R.;
RT   "The stress kinase MRK contributes to regulation of DNA damage
RT   checkpoints through a p38gamma-independent pathway.";
RL   J. Biol. Chem. 279:47652-47660(2004).
RN   [14]
RP   PHOSPHORYLATION BY PLK4.
RX   PubMed=19164942;
RA   Petrinac S., Ganuelas M.L., Bonni S., Nantais J., Hudson J.W.;
RT   "Polo-like kinase 4 phosphorylates Chk2.";
RL   Cell Cycle 8:327-329(2009).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 64-212.
RX   MEDLINE=22045891; PubMed=12049740; DOI=10.1016/S1097-2765(02)00527-0;
RA   Li J., Williams B.L., Haire L.F., Goldberg M., Wilker E., Durocher D.,
RA   Yaffe M.B., Jackson S.P., Smerdon S.J.;
RT   "Structural and functional versatility of the FHA domain in DNA-damage
RT   signaling by the tumor suppressor kinase Chk2.";
RL   Mol. Cell 9:1045-1054(2002).
RN   [16]
RP   VARIANT THR-157, AND VARIANT COLON CANCER TRP-145.
RX   MEDLINE=20085462; PubMed=10617473; DOI=10.1126/science.286.5449.2528;
RA   Bell D.W., Varley J.M., Szydlo T.E., Kang D.H., Wahrer D.C.R.,
RA   Shannon K.E., Lubratovich M., Versalis S.J., Isselbacher K.J.,
RA   Fraumeni J.F. Jr., Birch J.M., Li F.P., Garber J.E., Haber D.A.;
RT   "Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.";
RL   Science 286:2528-2531(1999).
RN   [17]
RP   VARIANT THR-157.
RX   MEDLINE=21354286; PubMed=11461078; DOI=10.1054/bjoc.2001.1858;
RA   Allinen M., Huusko P., Maentyniemi S., Launonen V., Winqvist R.;
RT   "Mutation analysis of the CHK2 gene in families with hereditary breast
RT   cancer.";
RL   Br. J. Cancer 85:209-212(2001).
RN   [18]
RP   VARIANT LFS2 TRP-145.
RX   MEDLINE=21575821; PubMed=11719428;
RA   Lee S.B., Kim S.H., Bell D.W., Wahrer D.C.R., Schiripo T.A.,
RA   Jorczak M.M., Sgroi D.C., Garber J.E., Li F.P., Nichols K.E.,
RA   Varley J.M., Godwin A.K., Shannon K.M., Harlow E., Haber D.A.;
RT   "Destabilization of CHK2 by a missense mutation associated with Li-
RT   Fraumeni Syndrome.";
RL   Cancer Res. 61:8062-8067(2001).
RN   [19]
RP   VARIANT MULTIPLE CANCERS LYS-59.
RX   PubMed=12052256; DOI=10.1186/bcr435;
RA   Ingvarsson S., Sigbjornsdottir B.I., Huiping C., Hafsteinsdottir S.H.,
RA   Ragnarsson G., Barkardottir R.B., Arason A., Egilsson V.,
RA   Bergthorsson J.T.;
RT   "Mutation analysis of the CHK2 gene in breast carcinoma and other
RT   cancers.";
RL   Breast Cancer Res. 4:R4-R4(2002).
RN   [20]
RP   VARIANTS GLY-117; GLN-137 AND HIS-180.
RX   MEDLINE=22340809; PubMed=12454775; DOI=10.1038/sj.bjc.6600637;
RA   Sodha N., Bullock S., Taylor R., Mitchell G., Guertl-Lackner B.,
RA   Williams R.D., Bevan S., Bishop K., McGuire S., Houlston R.S.,
RA   Eeles R.A.;
RT   "CHEK2 variants in susceptibility to breast cancer and evidence of
RT   retention of the wild type allele in tumours.";
RL   Br. J. Cancer 87:1445-1448(2002).
RN   [21]
RP   VARIANTS OSTEOSARCOMA SER-17 AND LEU-85.
RX   MEDLINE=21610705; PubMed=11746983; DOI=10.1002/gcc.1207;
RA   Miller C.W., Ikezoe T., Krug U., Hofmann W.K., Tavor S., Vegesna V.,
RA   Tsukasaki K., Takeuchi S., Koeffler H.P.;
RT   "Mutations of the CHK2 gene are found in some osteosarcomas, but are
RT   rare in breast, lung, and ovarian tumors.";
RL   Genes Chromosomes Cancer 33:17-21(2002).
RN   [22]
RP   VARIANTS PROSTATE CANCER LYS-64; PRO-145; ARG-167; CYS-180; HIS-180;
RP   CYS-181; HIS-181; LYS-239; PHE-251; HIS-318; PRO-323; CYS-327 AND
RP   LYS-476, AND VARIANT THR-157.
RX   MEDLINE=22428307; PubMed=12533788; DOI=10.1086/346094;
RA   Dong X., Wang L., Taniguchi K., Wang X., Cunningham J.M.,
RA   McDonnell S.K., Qian C., Marks A.F., Slager S.L., Peterson B.J.,
RA   Smith D.I., Cheville J.C., Blute M.L., Jacobsen S.J., Schaid D.J.,
RA   Tindall D.J., Thibodeau S.N., Liu W.;
RT   "Mutations in CHEK2 associated with prostate cancer risk.";
RL   Am. J. Hum. Genet. 72:270-280(2003).
RN   [23]
RP   VARIANTS GLY-117; TRP-145 AND THR-157.
RX   MEDLINE=22534962; PubMed=12610780; DOI=10.1086/373965;
RA   Schutte M., Seal S., Barfoot R., Meijers-Heijboer H., Wasielewski M.,
RA   Evans D.G., Eccles D., Meijers C., Lohman F., Klijn J.,
RA   van den Ouweland A., Brady A., Cole T., Collins A., Cox H.,
RA   Donaldson A., Eeles R., Evans G., Gregory H., Gray J., Houlston R.,
RA   Lalloo F., Lucassen A., Mackay J., Mitchell G., Morrison P.,
RA   Murday V., Narod S., Patterson J., Peretz T., Phelan C.M., Rogers M.,
RA   Schofield A., Tonin P., Weber B., Weber W., Futreal P.A.,
RA   Nathanson K.L., Weber B.L., Easton D.F., Stratton M.R., Rahman N.;
RT   "Variants in CHEK2 other than 1100delC do not make a major
RT   contribution to breast cancer susceptibility.";
RL   Am. J. Hum. Genet. 72:1023-1028(2003).
RN   [24]
RP   VARIANT THR-157.
RX   MEDLINE=22973597; PubMed=14612911; DOI=10.1038/sj.bjc.6601425;
RA   Seppaelae E.H., Ikonen T., Mononen N., Autio V., Roekman A.,
RA   Matikainen M.P., Tammela T.L.J., Schleutker J.;
RT   "CHEK2 variants associate with hereditary prostate cancer.";
RL   Br. J. Cancer 89:1966-1970(2003).
RN   [25]
RP   VARIANT THR-157.
RX   PubMed=15492928; DOI=10.1086/426403;
RA   Cybulski C., Gorski B., Huzarski T., Masojc B., Mierzejewski M.,
RA   Debniak T., Teodorczyk U., Byrski T., Gronwald J., Matyjasik J.,
RA   Zlowocka E., Lenner M., Grabowska E., Nej K., Castaneda J., Medrek K.,
RA   Szymanska A., Szymanska J., Kurzawski G., Suchy J., Oszurek O.,
RA   Witek A., Narod S.A., Lubinski J.;
RT   "CHEK2 is a multiorgan cancer susceptibility gene.";
RL   Am. J. Hum. Genet. 75:1131-1135(2004).
RN   [26]
RP   VARIANTS TRP-145 AND THR-157.
RX   PubMed=15535844; DOI=10.1186/bcr933;
RA   Friedrichsen D.M., Malone K.E., Doody D.R., Daling J.R.,
RA   Ostrander E.A.;
RT   "Frequency of CHEK2 mutations in a population based, case-control
RT   study of breast cancer in young women.";
RL   Breast Cancer Res. 6:R629-R635(2004).
RN   [27]
RP   VARIANT THR-157.
RX   PubMed=15087378; DOI=10.1158/0008-5472.CAN-04-0341;
RA   Cybulski C., Huzarski T., Gorski B., Masojc B., Mierzejewski M.,
RA   Debniak T., Gliniewicz B., Matyjasik J., Zlowocka E., Kurzawski G.,
RA   Sikorski A., Posmyk M., Szwiec M., Czajka R., Narod S.A., Lubinski J.;
RT   "A novel founder CHEK2 mutation is associated with increased prostate
RT   cancer risk.";
RL   Cancer Res. 64:2677-2679(2004).
RN   [28]
RP   VARIANT THR-157.
RX   PubMed=15095295; DOI=10.1002/ijc.20073;
RA   Dufault M.R., Betz B., Wappenschmidt B., Hofmann W., Bandick K.,
RA   Golla A., Pietschmann A., Nestle-Kraemling C., Rhiem K., Huettner C.,
RA   von Lindern C., Dall P., Kiechle M., Untch M., Jonat W., Meindl A.,
RA   Scherneck S., Niederacher D., Schmutzler R.K., Arnold N.;
RT   "Limited relevance of the CHEK2 gene in hereditary breast cancer.";
RL   Int. J. Cancer 110:320-325(2004).
RN   [29]
RP   VARIANT THR-157.
RX   PubMed=15239132; DOI=10.1002/ijc.20299;
RA   Kilpivaara O., Vahteristo P., Falck J., Syrjaekoski K., Eerola H.,
RA   Easton D., Bartkova J., Lukas J., Heikkilae P., Aittomaeki K.,
RA   Holli K., Blomqvist C., Kallioniemi O.-P., Bartek J., Nevanlinna H.;
RT   "CHEK2 variant I157T may be associated with increased breast cancer
RT   risk.";
RL   Int. J. Cancer 111:543-547(2004).
RN   [30]
RP   VARIANTS LEU-85 AND PHE-428.
RX   PubMed=15649950; DOI=10.1093/hmg/ddi052;
RA   Shaag A., Walsh T., Renbaum P., Kirchhoff T., Nafa K., Shiovitz S.,
RA   Mandell J.B., Welcsh P., Lee M.K., Ellis N., Offit K., Levy-Lahad E.,
RA   King M.-C.;
RT   "Functional and genomic approaches reveal an ancient CHEK2 allele
RT   associated with breast cancer in the Ashkenazi Jewish population.";
RL   Hum. Mol. Genet. 14:555-563(2005).
RN   [31]
RP   VARIANT THR-157.
RX   PubMed=15810020; DOI=10.1002/ijc.21022;
RA   Bogdanova N., Enbetaen-Dubrowinskaja N., Feshchenko S., Lazjuk G.I.,
RA   Rogov Y.I., Dammann O., Bremer M., Karstens J.H., Sohn C., Doerk T.;
RT   "Association of two mutations in the CHEK2 gene with breast cancer.";
RL   Int. J. Cancer 116:263-266(2005).
RN   [32]
RP   VARIANTS GLY-117; GLN-137; TRP-145; THR-157 AND HIS-180.
RX   PubMed=15818573; DOI=10.1002/path.1764;
RA   van Puijenbroek M., van Asperen C.J., van Mil A., Devilee P.,
RA   van Wezel T., Morreau H.;
RT   "Homozygosity for a CHEK2*1100delC mutation identified in familial
RT   colorectal cancer does not lead to a severe clinical phenotype.";
RL   J. Pathol. 206:198-204(2005).
CC   -!- FUNCTION: Regulates cell cycle checkpoints and apoptosis in
CC       response to DNA damage, particularly to DNA double-strand breaks.
CC       Inhibits CDC25C phosphatase by phosphorylation on 'Ser-216',
CC       preventing the entry into mitosis. May also play a role in
CC       meiosis. Regulates the TP53 tumor suppressor through
CC       phosphorylation at 'Thr-18' and 'Ser-20'.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Magnesium.
CC   -!- ENZYME REGULATION: Rapidly phosphorylated on Thr-68 by MLTK in
CC       response to DNA damage and to replication block. Kinase activity
CC       is also up-regulated by autophosphorylation.
CC   -!- INTERACTION:
CC       Q9NY61:AATF; NbExp=3; IntAct=EBI-1180783, EBI-372428;
CC       Q9Y248:GINS2; NbExp=1; IntAct=EBI-1180783, EBI-747491;
CC       P53350:PLK1; NbExp=3; IntAct=EBI-1180783, EBI-476768;
CC       Q15172:PPP2R5A; NbExp=1; IntAct=EBI-1180783, EBI-641666;
CC       Q15173:PPP2R5B; NbExp=1; IntAct=EBI-1180783, EBI-1369497;
CC       Q13362:PPP2R5C; NbExp=7; IntAct=EBI-1180783, EBI-1266156;
CC       Q16537:PPP2R5E; NbExp=3; IntAct=EBI-1180783, EBI-968374;
CC       P02340:Tp53 (xeno); NbExp=1; IntAct=EBI-1180783, EBI-474016;
CC       P55072:VCP; NbExp=2; IntAct=EBI-1180783, EBI-355164;
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Nucleus. Note=Isoform 10 is
CC       present throughout the cell.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Nucleus.
CC   -!- SUBCELLULAR LOCATION: Isoform 7: Nucleus.
CC   -!- SUBCELLULAR LOCATION: Isoform 9: Nucleus.
CC   -!- SUBCELLULAR LOCATION: Isoform 12: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=12;
CC       Name=1;
CC         IsoId=O96017-1; Sequence=Displayed;
CC       Name=2; Synonyms=ins2;
CC         IsoId=O96017-2; Sequence=VSP_014564, VSP_014567, VSP_014568;
CC         Note=Catalytically inactive;
CC       Name=3; Synonyms=del2-12;
CC         IsoId=O96017-3; Sequence=VSP_014559;
CC       Name=4; Synonyms=del2-3;
CC         IsoId=O96017-4; Sequence=VSP_014558;
CC         Note=Catalytically active;
CC       Name=5; Synonyms=del4;
CC         IsoId=O96017-5; Sequence=VSP_014565, VSP_014566;
CC       Name=6; Synonyms=sub3;
CC         IsoId=O96017-6; Sequence=VSP_014562, VSP_014563;
CC       Name=7; Synonyms=del9-12;
CC         IsoId=O96017-7; Sequence=VSP_014572, VSP_014573;
CC         Note=Catalytically inactive;
CC       Name=8; Synonyms=del7;
CC         IsoId=O96017-8; Sequence=VSP_014569, VSP_014570;
CC       Name=9; Synonyms=insx;
CC         IsoId=O96017-9; Sequence=VSP_014557;
CC         Note=Retains low level of catalytic activity;
CC       Name=10; Synonyms=iso2;
CC         IsoId=O96017-10; Sequence=VSP_014560, VSP_014561;
CC         Note=Catalytically inactive;
CC       Name=11; Synonyms=iso1;
CC         IsoId=O96017-11; Sequence=VSP_014556;
CC       Name=12; Synonyms=del9;
CC         IsoId=O96017-12; Sequence=VSP_014571;
CC         Note=Catalytically inactive;
CC   -!- TISSUE SPECIFICITY: High expression is found in testis, spleen,
CC       colon and peripheral blood leukocytes. Low expression is found in
CC       other tissues.
CC   -!- PTM: Phosphorylated by PLK4.
CC   -!- DISEASE: Defects in CHEK2 are associated with Li-Fraumeni syndrome
CC       2 (LFS2) [MIM:609265]; a highly penetrant familial cancer
CC       phenotype usually associated with inherited mutations in p53/TP53.
CC   -!- DISEASE: Defects in CHEK2 may be a cause of susceptibility to
CC       prostate cancer (PC) [MIM:176807]. It is a malignancy originating
CC       in tissues of the prostate. Most prostate cancers are
CC       adenocarcinomas that develop in the acini of the prostatic ducts.
CC       Other rare histopathologic types of prostate cancer that occur in
CC       approximately 5% of patients include small cell carcinoma,
CC       mucinous carcinoma, prostatic ductal carcinoma, transitional cell
CC       carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid
CC       cystic carcinoma (basaloid), signet-ring cell carcinoma and
CC       neuroendocrine carcinoma.
CC   -!- DISEASE: Defects in CHEK2 are found in some patients with
CC       osteosarcoma (OSRC) [MIM:259500].
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. CHK2 subfamily.
CC   -!- SIMILARITY: Contains 1 FHA domain.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CHEK2ID312.html";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/CHEK2";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/chek2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF086904; AAC83693.1; -; mRNA.
DR   EMBL; AJ131197; CAA10319.1; -; mRNA.
DR   EMBL; AF096279; AAD11784.1; -; mRNA.
DR   EMBL; AY551295; AAS58456.1; -; mRNA.
DR   EMBL; AY551296; AAS58457.1; -; mRNA.
DR   EMBL; AY551297; AAS58458.1; -; mRNA.
DR   EMBL; AY551298; AAS58459.1; -; mRNA.
DR   EMBL; AY551299; AAS58460.1; -; mRNA.
DR   EMBL; AY551300; AAS58461.1; -; mRNA.
DR   EMBL; AY551301; AAS58462.1; -; mRNA.
DR   EMBL; AY551302; AAS58463.1; -; mRNA.
DR   EMBL; AY551303; AAS58464.1; -; mRNA.
DR   EMBL; AY551304; AAS58465.1; -; mRNA.
DR   EMBL; AY551305; AAS58466.1; -; mRNA.
DR   EMBL; CR456418; CAG30304.1; -; mRNA.
DR   EMBL; AF174135; AAD48504.1; -; mRNA.
DR   EMBL; AB040105; BAB17231.1; -; mRNA.
DR   EMBL; AK290754; BAF83443.1; -; mRNA.
DR   EMBL; AY800241; AAV41895.1; -; Genomic_DNA.
DR   EMBL; AL121825; CAH73823.1; -; Genomic_DNA.
DR   EMBL; AL117330; CAH73823.1; JOINED; Genomic_DNA.
DR   EMBL; AL117330; CAH73875.1; -; Genomic_DNA.
DR   EMBL; AL121825; CAH73875.1; JOINED; Genomic_DNA.
DR   EMBL; AL121825; CAX11957.1; -; Genomic_DNA.
DR   EMBL; AL117330; CAX11957.1; JOINED; Genomic_DNA.
DR   EMBL; AL121825; CAX11958.1; -; Genomic_DNA.
DR   EMBL; AL117330; CAX11958.1; JOINED; Genomic_DNA.
DR   EMBL; AL121825; CAX11959.1; -; Genomic_DNA.
DR   EMBL; AL117330; CAX11959.1; JOINED; Genomic_DNA.
DR   EMBL; AL117330; CAX14026.1; -; Genomic_DNA.
DR   EMBL; AL121825; CAX14026.1; JOINED; Genomic_DNA.
DR   EMBL; AL117330; CAX14027.1; -; Genomic_DNA.
DR   EMBL; AL121825; CAX14027.1; JOINED; Genomic_DNA.
DR   EMBL; AL117330; CAX14028.1; -; Genomic_DNA.
DR   EMBL; AL121825; CAX14028.1; JOINED; Genomic_DNA.
DR   EMBL; CH471095; EAW59755.1; -; Genomic_DNA.
DR   EMBL; BC004207; AAH04207.1; -; mRNA.
DR   IPI; IPI00014072; -.
DR   IPI; IPI00030746; -.
DR   IPI; IPI00423146; -.
DR   IPI; IPI00423149; -.
DR   IPI; IPI00423156; -.
DR   IPI; IPI00423157; -.
DR   IPI; IPI00607619; -.
DR   IPI; IPI00607680; -.
DR   IPI; IPI00607709; -.
DR   IPI; IPI00607739; -.
DR   IPI; IPI00607753; -.
DR   IPI; IPI00607851; -.
DR   RefSeq; NP_001005735.1; -.
DR   RefSeq; NP_009125.1; -.
DR   RefSeq; NP_665861.1; -.
DR   UniGene; Hs.291363; -.
DR   UniGene; Hs.505297; -.
DR   PDB; 1GXC; X-ray; 2.70 A; A/D/G/J=64-212.
DR   PDB; 2CN5; X-ray; 2.25 A; A=210-531.
DR   PDB; 2CN8; X-ray; 2.70 A; A=210-531.
DR   PDB; 2W0J; X-ray; 2.05 A; A=210-531.
DR   PDB; 2W7X; X-ray; 2.07 A; A=210-531.
DR   PDB; 2WTC; X-ray; 3.00 A; A=210-531.
DR   PDB; 2WTD; X-ray; 2.75 A; A=210-531.
DR   PDB; 2WTI; X-ray; 2.50 A; A=210-531.
DR   PDB; 2WTJ; X-ray; 2.10 A; A=210-531.
DR   PDB; 3I6U; X-ray; 3.00 A; A/B=84-502.
DR   PDB; 3I6W; X-ray; 3.25 A; A/B/C/D/E/F/G/H=70-512.
DR   PDBsum; 1GXC; -.
DR   PDBsum; 2CN5; -.
DR   PDBsum; 2CN8; -.
DR   PDBsum; 2W0J; -.
DR   PDBsum; 2W7X; -.
DR   PDBsum; 2WTC; -.
DR   PDBsum; 2WTD; -.
DR   PDBsum; 2WTI; -.
DR   PDBsum; 2WTJ; -.
DR   PDBsum; 3I6U; -.
DR   PDBsum; 3I6W; -.
DR   ProteinModelPortal; O96017; -.
DR   DIP; DIP-24270N; -.
DR   IntAct; O96017; 36.
DR   MINT; MINT-124588; -.
DR   STRING; O96017; -.
DR   PhosphoSite; O96017; -.
DR   PRIDE; O96017; -.
DR   Ensembl; ENST00000328354; ENSP00000329178; ENSG00000183765.
DR   Ensembl; ENST00000404276; ENSP00000385747; ENSG00000183765.
DR   Ensembl; ENST00000405598; ENSP00000386087; ENSG00000183765.
DR   GeneID; 11200; -.
DR   KEGG; hsa:11200; -.
DR   UCSC; uc003adu.1; human.
DR   UCSC; uc003adv.1; human.
DR   UCSC; uc003ady.1; human.
DR   CTD; 11200; -.
DR   GeneCards; GC22M029083; -.
DR   HGNC; HGNC:16627; CHEK2.
DR   HPA; CAB002030; -.
DR   HPA; HPA001878; -.
DR   MIM; 176807; phenotype.
DR   MIM; 259500; phenotype.
DR   MIM; 604373; gene+phenotype.
DR   MIM; 609265; phenotype.
DR   Orphanet; 1331; Familial prostate cancer.
DR   Orphanet; 145; Hereditary breast and ovarian cancer syndrome.
DR   Orphanet; 524; Li-Fraumeni syndrome.
DR   Orphanet; 668; Osteosarcoma.
DR   PharmGKB; PA404; -.
DR   eggNOG; prNOG16187; -.
DR   HOVERGEN; HBG108055; -.
DR   OMA; KARFTTE; -.
DR   PhylomeDB; O96017; -.
DR   BRENDA; 2.7.11.1; 247.
DR   Pathway_Interaction_DB; foxm1pathway; FOXM1 transcription factor network.
DR   Reactome; REACT_1538; Cell Cycle Checkpoints.
DR   NextBio; 42629; -.
DR   ArrayExpress; O96017; -.
DR   Bgee; O96017; -.
DR   Genevestigator; O96017; -.
DR   GermOnline; ENSG00000183765; Homo sapiens.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0000077; P:DNA damage checkpoint; TAS:UniProtKB.
DR   GO; GO:0008630; P:DNA damage response, signal transduction re...; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IEA:InterPro.
DR   GO; GO:0010149; P:senescence; IDA:BHF-UCL.
DR   InterPro; IPR020636; Ca/CaM-dep_prot_kinase-like.
DR   InterPro; IPR000253; FHA_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR020648; Ser/Thr_prot_kinase_Chk2.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   InterPro; IPR008984; SMAD_FHA_domain.
DR   Gene3D; G3DSA:2.60.200.20; FHA; 1.
DR   PANTHER; PTHR22982; Ca/CaM-dep_prot_kinase-like; 1.
DR   PANTHER; PTHR22982:SF26; Ser/Thr_prot_kinase_Chk2; 1.
DR   Pfam; PF00498; FHA; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00240; FHA; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   SUPFAM; SSF49879; SMAD_FHA; 1.
DR   PROSITE; PS50006; FHA_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; FALSE_NEG.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle;
KW   Complete proteome; Disease mutation; Kinase; Li-Fraumeni syndrome;
KW   Magnesium; Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN         1    543       Serine/threonine-protein kinase Chk2.
FT                                /FTId=PRO_0000085858.
FT   DOMAIN      113    175       FHA.
FT   DOMAIN      220    486       Protein kinase.
FT   NP_BIND     226    234       ATP (By similarity).
FT   ACT_SITE    347    347       Proton acceptor.
FT   BINDING     249    249       ATP (By similarity).
FT   MOD_RES      68     68       Phosphothreonine; by MLTK.
FT   VAR_SEQ      75    392       Missing (in isoform 11).
FT                                /FTId=VSP_014556.
FT   VAR_SEQ     107    487       Missing (in isoform 3).
FT                                /FTId=VSP_014559.
FT   VAR_SEQ     107    197       Missing (in isoform 4).
FT                                /FTId=VSP_014558.
FT   VAR_SEQ     107    107       E -> ETESGHVTQSDLELLLSSDPPASASQSAGIRGVRHH
FT                                PRPVCSLK (in isoform 9).
FT                                /FTId=VSP_014557.
FT   VAR_SEQ     131    147       KRTDKYRTYSKKHFRIF -> EFRSYSFYLP (in
FT                                isoform 10).
FT                                /FTId=VSP_014560.
FT   VAR_SEQ     148    543       Missing (in isoform 10).
FT                                /FTId=VSP_014561.
FT   VAR_SEQ     150    165       VGPKNSYIAYIEDHSG -> ENLSCPYRIWFNFCLF (in
FT                                isoform 6).
FT                                /FTId=VSP_014562.
FT   VAR_SEQ     166    543       Missing (in isoform 6).
FT                                /FTId=VSP_014563.
FT   VAR_SEQ     198    224       VFVFFDLTVDDQSVYPKALRDEYIMSK -> EKILKIYSLS
FT                                RFSKIRRGAVAHVFNPS (in isoform 2).
FT                                /FTId=VSP_014564.
FT   VAR_SEQ     199    203       FVFFD -> VPVER (in isoform 5).
FT                                /FTId=VSP_014565.
FT   VAR_SEQ     204    543       Missing (in isoform 5).
FT                                /FTId=VSP_014566.
FT   VAR_SEQ     228    234       SGACGEV -> GRGWQIT (in isoform 2).
FT                                /FTId=VSP_014567.
FT   VAR_SEQ     235    543       Missing (in isoform 2).
FT                                /FTId=VSP_014568.
FT   VAR_SEQ     283    289       PCIIKIK -> DGRGRAV (in isoform 8).
FT                                /FTId=VSP_014569.
FT   VAR_SEQ     290    543       Missing (in isoform 8).
FT                                /FTId=VSP_014570.
FT   VAR_SEQ     337    365       Missing (in isoform 12).
FT                                /FTId=VSP_014571.
FT   VAR_SEQ     337    339       YLH -> MKT (in isoform 7).
FT                                /FTId=VSP_014572.
FT   VAR_SEQ     340    543       Missing (in isoform 7).
FT                                /FTId=VSP_014573.
FT   VARIANT      17     17       A -> S (in osteosarcoma; somatic
FT                                mutation; might influence susceptibility
FT                                to breast cancer; does not cause protein
FT                                abrogation in familial colorectal
FT                                cancer).
FT                                /FTId=VAR_019101.
FT   VARIANT      59     59       T -> K (in multiple cancers).
FT                                /FTId=VAR_026630.
FT   VARIANT      64     64       E -> K (in prostate cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_019107.
FT   VARIANT      85     85       P -> L (in osteosarcoma; is a neutral
FT                                allele among Ashkenazi Jewish women;
FT                                dbSNP:rs17883862).
FT                                /FTId=VAR_019102.
FT   VARIANT     117    117       R -> G (in dbSNP:rs28909982).
FT                                /FTId=VAR_022461.
FT   VARIANT     137    137       R -> Q (might influence susceptibility to
FT                                breast cancer; does not cause protein
FT                                abrogation in familial colorectal
FT                                cancer).
FT                                /FTId=VAR_022462.
FT   VARIANT     145    145       R -> P (in prostate cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_019108.
FT   VARIANT     145    145       R -> W (in colon cancer and LFS2; does
FT                                not cause protein abrogation in familial
FT                                colorectal cancer).
FT                                /FTId=VAR_008554.
FT   VARIANT     157    157       I -> T (might influence susceptibility to
FT                                diffferent types of cancer; does not
FT                                cause protein abrogation in familial
FT                                colorectal cancer; dbSNP:rs17879961).
FT                                /FTId=VAR_008555.
FT   VARIANT     167    167       G -> R (in prostate cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_019109.
FT   VARIANT     180    180       R -> C (in prostate cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_019103.
FT   VARIANT     180    180       R -> H (in prostate cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_019110.
FT   VARIANT     181    181       R -> C (in prostate cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_019104.
FT   VARIANT     181    181       R -> H (in prostate cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_019105.
FT   VARIANT     239    239       E -> K (in prostate cancer; germline
FT                                mutation).
FT                                /FTId=VAR_019106.
FT   VARIANT     251    251       I -> F (in prostate cancer; germline
FT                                mutation).
FT                                /FTId=VAR_019111.
FT   VARIANT     318    318       R -> H (in prostate cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_019112.
FT   VARIANT     323    323       T -> P (in prostate cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_019113.
FT   VARIANT     327    327       Y -> C (in prostate cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_019114.
FT   VARIANT     347    347       D -> N (in dbSNP:rs28909980).
FT                                /FTId=VAR_029154.
FT   VARIANT     406    406       R -> H (in dbSNP:rs299671).
FT                                /FTId=VAR_024572.
FT   VARIANT     428    428       S -> F (increases breast cancer risk
FT                                approximately 2-fold among Ashkenazi
FT                                Jewish women).
FT                                /FTId=VAR_022463.
FT   VARIANT     436    436       L -> M (in dbSNP:rs17882922).
FT                                /FTId=VAR_021117.
FT   VARIANT     446    446       N -> K (in dbSNP:rs17880867).
FT                                /FTId=VAR_021118.
FT   VARIANT     447    447       F -> I (in dbSNP:rs17881473).
FT                                /FTId=VAR_021119.
FT   VARIANT     448    448       I -> S (in dbSNP:rs17886163).
FT                                /FTId=VAR_021120.
FT   VARIANT     476    476       T -> K (in prostate cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_019115.
FT   VARIANT     500    500       S -> C (in dbSNP:rs28909981).
FT                                /FTId=VAR_029155.
FT   VARIANT     501    501       E -> K (in dbSNP:rs17883172).
FT                                /FTId=VAR_021121.
FT   VARIANT     512    512       L -> V (in dbSNP:rs17882942).
FT                                /FTId=VAR_021122.
FT   MUTAGEN      68     68       T->A: Loss of activation and
FT                                phosphorylation.
FT   MUTAGEN     347    347       D->A: Loss of kinase activity.
FT   MUTAGEN     368    368       D->N: Loss of autophosphorylation
FT                                activity.
FT   STRAND       94     98
FT   STRAND      106    108
FT   STRAND      110    118
FT   STRAND      122    124
FT   HELIX       128    132
FT   HELIX       135    138
FT   STRAND      144    150
FT   STRAND      154    162
FT   STRAND      168    170
FT   STRAND      180    182
FT   STRAND      187    193
FT   STRAND      197    203
FT   HELIX       214    219
FT   STRAND      220    228
FT   STRAND      230    239
FT   TURN        240    243
FT   STRAND      244    252
FT   HELIX       270    279
FT   STRAND      288    302
FT   HELIX       309    312
FT   HELIX       321    340
FT   HELIX       350    352
FT   STRAND      353    361
FT   STRAND      364    366
FT   HELIX       378    384
FT   HELIX       388    390
FT   HELIX       393    397
FT   TURN        398    403
FT   HELIX       407    422
FT   STRAND      429    431
FT   HELIX       436    442
FT   HELIX       449    452
FT   HELIX       457    466
FT   TURN        471    473
FT   HELIX       477    481
FT   HELIX       484    486
FT   HELIX       489    502
SQ   SEQUENCE   543 AA;  60915 MW;  28890ACF3C1F3408 CRC64;
     MSRESDVEAQ QSHGSSACSQ PHGSVTQSQG SSSQSQGISS SSTSTMPNSS QSSHSSSGTL
     SSLETVSTQE LYSIPEDQEP EDQEPEEPTP APWARLWALQ DGFANLECVN DNYWFGRDKS
     CEYCFDEPLL KRTDKYRTYS KKHFRIFREV GPKNSYIAYI EDHSGNGTFV NTELVGKGKR
     RPLNNNSEIA LSLSRNKVFV FFDLTVDDQS VYPKALRDEY IMSKTLGSGA CGEVKLAFER
     KTCKKVAIKI ISKRKFAIGS AREADPALNV ETEIEILKKL NHPCIIKIKN FFDAEDYYIV
     LELMEGGELF DKVVGNKRLK EATCKLYFYQ MLLAVQYLHE NGIIHRDLKP ENVLLSSQEE
     DCLIKITDFG HSKILGETSL MRTLCGTPTY LAPEVLVSVG TAGYNRAVDC WSLGVILFIC
     LSGYPPFSEH RTQVSLKDQI TSGKYNFIPE VWAEVSEKAL DLVKKLLVVD PKARFTTEEA
     LRHPWLQDED MKRKFQDLLS EENESTALPQ VLAQPSTSRK RPREGEAEGA ETTKRPAVCA
     AVL
//
